Table 1.

Clinical features of the patients before lung biopsy and after treatment^*

Disease, patient/age	Clinical features before lung biopsy								Clinical features after treatment
	Disease duration, years	Subtype	Anti–topo I	Tobacco use	MRSS	FVC, % predicted	DLco, % predicted	FibMax	FVC, % predicted	FibMax
NSIP
1/42	3	dcSSc	+	No	23	72	NA	2	NA	5
2/50	15	dcSSc	+	Former	15.5	88	NA	10	53	NA
3/44	10	dcSSc	–	Former	45	68	77	NA	60	13
4/41	8	dcSSc	–	No	24	70	44	4	NA	5
5/27	1	lcSSc	–	No	19	84	51	5	73	12
6/55	16	lcSSc	–	No	12	61	45	9	80	16
7/53	7	lcSSc	–	No	5	55	38	14	48	NA
8/57	6	dcSSc	–	No	21	84	59	NA	86	NA
9/43	1	dcSSc	–	No	46	78	NA	7	73	31
10/46	4	lcSSc	+	No	10	70	NA	7	38	16
11/45	1	lcSSc	–	No	0	74	91	7	75	8
12/24	13	dcSSc	+	No	34.5	68	74	2	64	NA
13/30	7	lcSSc	–	Yes	17	74	NA	18	75	14
14/57	9	lcSSc	+	No	7	61	NA	5	88	9
15/40	6	dcSSc	+	No	16	70	63	2	51	13
16/41	2	dcSSc	+	No	28.5	65	74	2	NA	NA
CLF
1/38	5	lcSSc	+	No	4	48	39	NA	NA	NA
2/48	3	dcSSc	+	No	27	54	41	5	NA	NA
3/53	23	lcSSc	–	No	13.5	81	89	NA	105	NA
4/51	13	lcSSc	–	No	6.5	76	66	7	60	10
5/31	3	dcSSc	+	No	12	81	67	11	86	14

^*Anti–topo I = anti–topoisomerase I; MRSS = modified Rodnan skin thickness score; FVC = forced vital capacity; DLco = diffusing capacity for carbon monoxide; FibMax = sum of all scores in 6 lung zones; NSIP = nonspecific interstitial pneumonia; dcSSc = diffuse cutaneous systemic sclerosis; NA= not available; lcSSc = limited cutaneous systemic sclerosis; CLF= centrilobular fibrosis.